Adalimumab in non-infectious uveitis, towards a real-world therapeutic paradigm beyond inflammation control: A multicenter cross-sectional study
{{output}}
Background: To evaluate the real-world long-term efficacy and safety of adalimumab (ADA) in refractory non-infectious uveitis (NIU), analyzing clinical outcomes, treatment adjustments, and the potential role of ADA trough levels ... ...
